Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLIER: Early ART in Acute HIV-1 Infection
NCT02859558Phase 2Completed
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of bictegravir + emtricitabine + tenofovir alafenamide, tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1). Started Jan 2017; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidetenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02859558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859558.